Citius Oncology signs distribution deal with McKesson for LYMPHIR launch

Citius Oncology Inc. (NASDAQ: CTOR) announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK) for its cancer therapy LYMPHIR, according to a company statement.

Under the agreement, McKesson will serve as an authorized distributor for LYMPHIR (denileukin diftitox-cxdl), which received FDA approval in August 2024 for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.

The McKesson agreement completes Citius Oncology's U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. The company plans to launch the therapy commercially in the fourth quarter of 2025.

"This agreement marks the final major component of our U.S. distribution strategy and reflects our deep commitment to ensuring that physicians and patients have timely access to LYMPHIR," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals.

McKesson, headquartered in Irving, Texas, is described as a global leader in healthcare supply chain management and medical products distribution. The company supports thousands of hospitals, clinics, and pharmacies across the United States.

Citius Oncology stated it has now finalized distribution agreements with all three of the largest U.S. pharmaceutical wholesalers and specialty distributors. The company reported that LYMPHIR has received a permanent J-code assignment (J9161) and NCCN guideline inclusion.

Citius Oncology is the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (NASDAQ: CTXR), which owns 79% of the oncology unit.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• Ocean Power Technologies revises fiscal 2026 results after audit
• REPAY joins Visa Platform Connect to serve ISO and ISV clients